Work

Comparative Analysis of CAR T Cells with Dual Specificity for CD19 and CD20

Year: 2024

Type: article

Abstract: CAR T-cell therapy of patients with B-cell malignancies demonstrates high efficacy and an acceptable safety profile. However, some patients do not respond to treatment or quickly relapse. One of the reasons for an inadequate response to CAR T-cell therapy may be the emergence of cancer cells escape variants that do not express the epitope recognized by the CAR. Using CAR T-cells with dual specificity could help mitigate this issue. In this study, we developed CAR T-cells specific to human CD19 and CD20 by exploring four configurations of antigen-recognition domains: two in the biCAR format and two in the dualCAR format. Expression of two independent CARs (dualCAR) driven by a single promoter was found to be the most promising format.

Source: Russian Journal for Personalized Medicine

DOI: 10.18705/2782-3806-2024-4-5-413-420

Authors: T. N. Belovezhets, A. A. Gorchakov, K. A. Samochernykh, S. V. Kulemzin

Institution: Federal Almazov North-West Medical Research Centre

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4404509639

FWCI:

Cites: 14

Cited by:

Related to: 10